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Abstract
Peritoneal fibrosis is a common complication of abdominal and pelvic surgery, and can also be triggered by
peritoneal dialysis, resulting in treatment failure. In these settings, fibrosis is driven by activated myofibroblasts
that are considered to be partly derived by mesothelial-to-mesenchymal transition (MMT). We hypothesized
that, if the molecular signature of MMT could be better defined, these insights could be exploited to block
this pathological cellular transition. Rat peritoneal mesothelial cells were purified by the use of an antibody
against HBME1, a protein present on mesothelial cell microvilli, and streptavidin nanobead technology. After
exposure of sorted cells to a well-known mediator of MMT, transforming growth factor (TGF)-1, RNA sequencing
was undertaken to define the transcriptomes of mesothelial cells before and during early-phase MMT. MMT was
associated with dysregulation of transcripts encoding molecules involved in insulin-like growth factor (IGF) and
bone morphogenetic protein (BMP) signalling. The application of either recombinant BMP4 or IGF-binding protein
4 (IGFBP4) ameliorated TGF-1-induced MMT in culture, as judged from the retention of epithelial morphological
and molecular phenotypes, and reduced migration. Furthermore, peritoneal tissue from peritoneal dialysis patients
showed less prominent immunostaining than control tissue for IGFBP4 and BMP4 on the peritoneal surface. In
a mouse model of TGF-1-induced peritoneal thickening, BMP4 immunostaining on the peritoneal surface was
attenuated as compared with healthy controls. Finally, genetic lineage tracing of mesothelial cells was used in mice
with peritoneal injury. In this model, administration of BMP4 ameliorated the injury-induced shape change and
migration of mesothelial cells. Our findings demonstrate a distinctive MMT signature, and highlight the therapeutic
potential for BMP4, and possibly IGFBP4, to reduce MMT.
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Epithelia form sheets and tubules conferring physi-
cal integrity and performing physiological functions.
Epithelial-to-mesenchymal transition (EMT) occurs in
normal development during gastrulation and neural crest
migration. EMT is characterized by disrupted cell–cell
adhesion and apical–basolateral polarity, cytoskeletal
reorganization, detachment from basement membranes,
and the generation of motile mesenchymal cells. The
reverse process, mesenchymal-to-epithelial transition,
occurs during somitogenesis and nephrogenesis [1,2].
Mesothelial cells (MCs) are epithelial-like cells lining
the coelomic cavities and the organs that they contain.
MCs have junctional complexes and apical–basolateral
polarity, and adhere to a basement membrane. MCs
secrete glycosaminoglycans and surfactant, permitting
frictionless gliding of organs, and act as a barrier
expressing inflammation-modulating cytokines. MCs in
vivo not only express cytokeratins, which is characteris-
tic of epithelia, but also vimentin, which is more typical
of mesenchyme [3]. In normal development, some MCs
undergo mesothelial-to-mesenchymal transition (MMT)
to form vascular smooth muscle [4,5]. In development
and cancer, the transcription factors Snail, Twist and
Slug drive EMT [6,7]. MCs are not typical epithelial
cells, so the biological characteristics ofMMT and EMT
may not be identical.
Fibrosis is an aberrant response to injury, and
therapies to slow or reverse fibrosis are urgently
needed. α-Smooth muscle actin (αSMA)-expressing
myofibroblasts drive fibrosis, and it has been proposed
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that EMT generates some of these cells [1,8,9]. In
response to injury, MCs can undergo MMT [10–13].
For example, after injection of labelled MCs into
the peritoneal cavity, they appear in the regenerating
mesothelial layer and in the submesothelial layer [14].
Peritoneal fibrosis can be triggered by peritoneal dial-
ysis, causing treatment failure, and by surgery, causing
adhesions. Targeting of MMT may therefore prevent
scarring. Mesothelial damage by peritoneal dialysis or
surgery initiates the production of profibrotic media-
tors, notably transforming growth factor (TGF)-β1 [3].
We hypothesized that, if the molecular signature of
TGF-β1-induced MMT could be defined, these insights
could be exploited to ameliorate MMT.
Materials and methods
Animals
Animal experiments were undertaken according to
ARRIVE guidelines, and were approved by the Review
Boards of the Universities of Manchester and Liverpool,
and by the Home Office.
Isolation, purification and culture of rat MCs
Omental tissue was dissected from 9–12-week-old
female Wistar rats weighing 220–250 g (Charles
River, Harlow, UK). Tissue was dissociated in 0.25%
trypsin–EDTA (Sigma-Aldrich, Gillingham, UK) for
20min at 37 ∘C. Cells were incubatedwith HBME1 anti-
body (M3505, 1:50; Dako, Cambridge, UK) for 30min
in 3% bovine serum albumin in phosphate-buffered
saline (PBS). Cells were washed and incubated for
30min with biotinylated secondary antibody (BA2020,
1:100; Vector Laboratories, Peterborough, UK). Fol-
lowing further washes, 1.5× 106 cells were incubated
with streptavidin-coated magnetic nanobeads (Biole-
gend, London, UK) for 15min, and then placed in
a MojoSort magnet (Biolegend) for 5min. Uncap-
tured cells were decanted, and the remainder were
resuspended in culture media comprising high-glucose
Dulbecco’s modified Eagle’s medium supplemented
with 15% fetal bovine serum (FBS), 4mML-glutamine
(Sigma-Aldrich), 1% v/v penicillin/streptomycin, and
0.4 μg/ml hydrocortisone (Sigma-Aldrich). In other
experiments, cells from trypsinized omentum were
subjected to fluorescence-activated cell sorting (FACS),
as described previously [15]. Cells were processed as
for magnetic bead sorting, but HBME1 antibody was
detected with IgMAlexa488 (A-21042, 1:1000; Thermo
Fisher Scientific, Runcorn, UK). Cells were seeded at
5× 104/cm2 in multiwell plates. After comparison of the
two methods, subsequent experiments were performed
with Mojo purification. After 48–72 h of culture follow-
ing enrichment, cells werewashedwithHanks’ balanced
salt solution, and the medium was changed every other
day for up to 10–11 days. Cells were then placed in
low-serum (5% FBS) medium. Cells were exposed to
1 ng/ml TGF-β1 for 48 h (R&DSystems, Abington, UK)
and/or 50 ng/ml bone morphogenetic protein (BMP) 4
(Biolegend) and/or 50 ng/ml insulin-like growth factor
(IGF)-binding protein (IGFBP) 4 (Biolegend).
RNA sequencing (RNA-seq) and quantitative
polymerase chain reaction (qPCR)
These are detailed in supplementary material, Supple-
mentary materials and methods. For RNA-seq, differ-
entially expressed transcripts were defined as those for
which the log2(fold change) was ≥0.36 or≤−0.36 ver-
sus controls, and for which there was a statistical signif-
icance of p< 0.05, corrected for multiple comparisons.
(Fold change= test value/control value.) RNA-seq data
are available at ArrayExpress E-MTAB-5998.
Immunostaining, cell migration assay,
and enzyme-linked immunosorbent assay (ELISA)
Details are given in supplementary material, Supple-
mentary materials and methods.
TGF-β1-induced peritoneal fibrosis and peritoneal
MC lineage tracing in mice
Two models of peritoneal injury were studied. In the
first, tissues from wild-type C57BL/6 J mice that had
received intraperitoneal adenovirus expressing TGF-β1
were analysed; we previously reported that this led to
submesothelial fibrosis in vivo [16]. In a second model,
we combined surgical abrasion of the peritoneum [17]
with an MC lineage tracing strategy, similar to that
described by Lua et al [18], but using LacZ rather than
GFP. Detailed protocols are given in supplementary
material, Supplementary materials and methods.
Human tissue analyses
After informed consent and ethical approval (REC
06/Q1407/94 and 14/NE/0059), peritoneum samples
were collected from patients undergoing hernia repair
(n= 4) and from end-stage kidney disease patients
who had undergone peritoneal dialysis (n= 4). Tis-
sues were fixed in 4% paraformaldehyde for 24 h,
and processed into paraffin blocks, from which 7-μm
sections were taken and permeabilized with 0.2% Triton
in PBS, and then incubated with primary antibodies
against HBME1 (Dako; M3505, 1:50), IGFBP4 (Abcam
Cambridge, UK; ab83846, 1:700) or BMP4 (Abcam;
ab39973, 1:100) overnight at 4 ∘C. Sections were
incubated with the Rabbit IgG Specific horseradish
peroxidase/3,3′-diaminobenzidine (ABC) detection kit
(Abcam). Images were obtained with a light microscope
(Olympus, Southend-on-Sea, UK) and Image-Pro Plus
software (Media Cybernetics, Cambridge, UK).
Statistics
Analysis for RNA-seq data is outlined above. All other
datasets were normally distributed, and so are presented
as mean±standard error of the mean (SEM). Student’s
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Figure 1. MC enrichment with HBME1 as a surface marker. (A) Fluorescence microscopy of rat omentum, showing all nuclei stained
with 4′,6-diamidino-2-phenylindole (DAPI), the MC apical surface immunostained for HBME1, and a merged overlay image. Scale bars:
50 μm. (B) Phase contrast and immunofluorescence images of primary cultures of unsorted, HBME1 FACS-sorted and HBME1 magnetic
bead (Mojo)-sorted cells; note the prominent cobblestone phenotype of the sorted cells. Scale bars: 200 μm. Relative to unsorted cells,
both FACS-sorted and Mojo-sorted cells are markedly enriched for HBME1. Note the presence of both Wt1-positive (arrowhead) and
Wt1-negative (arrow) nuclei in the unsorted population stained with DAPI. Scale bars: 50 μm. (C) HBME1 enrichment was confirmed by
measuring the pixels of positive immunostaining normalized to DAPI nuclei in FACS-sorted and Mojo-sorted cells (n= 6; mean±SEM). (D)
The percentage of Wt1-positive nuclei was increased following either FACS or Mojo sorting (n= 3; mean±SEM). (E) Cells were cultured
for 48 h with or without 1 ng/ml TGF-β1. Note the disruption of the cobblestone phenotype under TGF-β1 treatment, with cells becoming
elongated. Scale bars: 50 μm. (F) Fluorescence microscopy of cells at 48 h, demonstrating that exposure to TGF-β1 was associated with
disruption of the reticular cell–cell junctional ZO1 pattern, with more prominent cytoplasmic immunostaining for vimentin (Vim) and
αSMA. Nuclei were stained with DAPI. Scale bars: 50 μm.
t-tests or ANOVA with Tukey post hoc tests were used to
compare groups. Analyses were performed with Graph-
Pad Prism 6 (GraphPad Software, La Jolla, CA, USA).
Results
MC enrichment
In rat omentum sections, HBME1 was immunodetected
in MCs (Figure 1A), but adipose and connective tissue
were negative. Primary cultures of omental cells that
had been selected after binding to the HBME1 antibody
either by FACS or magnetic bead sorting (Mojo) showed
an enhanced cobblestone appearance versus unsorted
cells (Figure 1B). FACS and magnetic bead sorting
each resulted in significant enrichment of cells express-
ing HBME1 (Figure 1B,C) or Wt1 (Figure 1B,D), an
MC transcription factor [4,5]. Unsorted cells showed
a mean HBME1 immunostaining level of ≈27 000
pixels/nucleus, which rose after HBME1 FACS to
162 000 (p= 0.022) or after magnetic bead sorting
to 192 000 (p= 0.005). Wt1 was immunodetected in
approximately half of all nuclei of unsorted cells, rising
to 90% after HBME1 FACS sorting (p= 0.022) and to
92% after HBME1 magnetic bead sorting (p= 0.017).
Induction of MMT in cell culture
Mojo-sorted MCs were exposed to TGF-β1, a driver
of both MMT and peritoneal fibrosis [19,20]. After
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018; 245: 491–501
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48 h, untreated MCs maintained their cobblestone mor-
phology (Figure 1E), whereas parallel cultures exposed
to 1 ng/ml TGF-β1 progressively lost their epithelioid
appearance and acquired an irregular elongated mor-
phology (Figure 1E). Primary cultures of sorted cells
showed positive immunostaining for ZO1, a tight junc-
tion protein, and vimentin, an intermediate filament pro-
tein (Figure 1F), as expressed by MCs in vivo [21,22].
Immunostaining for E-cadherin was barely detectable,
whereas MCF7 breast epithelial cells showed promi-
nent cell–cell junction immunostaining (supplementary
material, Figure S1). On immunohistochemistry, the
mesothelial layer of rat omentum in vivo was negative
for E-cadherin, whereas nearby pancreatic ductal cells
were positive (supplementary material, Figure S1). In
TGF-β1-exposured Mojo-sorted MCs: ZO1 became less
prominent at cell–cell junctions, instead appearing in a
cytoplasmic pattern; vimentin became more prominent;
and αSMA, a smoothmuscle contractile protein, became
upregulated versus untreated cells (Figure 1F). There-
fore, this protocol induced certain phenotypic changes
considered to be typical of MMT [23,24].
Gene expression in purified MCs
To define the transcriptome of purified MCs, we under-
took RNA-seq. In MCs exposed to 1 ng/ml TGF-β1
for 48 h, the levels of 834 transcripts increased, and
the levels of 487 transcripts were decreased, versus
cells cultured without exogenous TGF-β1. Unsuper-
vised hierarchical clustering clearly distinguished
between the two groups (Figure 2A). The volcano
plot in Figure 2B is annotated for changed ‘epithe-
lial signature’ transcripts; changed transcripts in this
class are listed in supplementary material, Table S1.
Among downregulated transcripts were: Cng, encod-
ing the tight junction protein cingulin; Cldn2 and
Cldn15, encoding tight junction claudins; Col4a3
and Col4a4, encoding epithelial basement membrane
collagens; Itga3, Itga6, Itgb3, and Itgb4, encoding
integrins; Krt13, Krt18, Krt19, and Krt23, encoding
keratin intermediate filaments; Lamb2 and Lamb3,
encoding laminin B2 and laminin 3; Podxl, encoding
sialomucin podocalyxin-like protein 1; Ppl, encod-
ing the desmosomal protein periplakin; and Upk3b,
encoding uroplakin 3B, a plasma membrane protein
that is characteristic of mesothelia in vivo [25]. Control
cells expressed high levels of Wt1, and Msln, encoding
the glycosylphosphatidylinositol-anchored cell surface
protein mesothelin [26], but only low levels of Cdh1,
encoding the cell–cell adhesion protein, E-cadherin.
Moreover, levels of these three transcripts did not
significantly change upon TGF-β1 exposure. Notably,
Sfn levels rose after exposure to TGF-β1; this transcript
encodes stratifin, which has been linked to epithelial
differentiation [27]. qPCR was undertaken (Figure 2C)
for a subset of transcripts (Cdh1, Cng, Col4a3, Col4a4,
Pdxl, Snai1, Tjp1, Upk3b, and Vim), with generally sim-
ilar findings to those of RNA-seq, although the decrease
in the level of Tjp1 was not significant. Notably, Cdh1
was detectable, but at a very low level by RNA-seq,
and its level was unchanged by TGF-β1 (supple-
mentary material, Table S1). E-cadherin, the encoded
protein, was not detected in vivo, and was barely
detected in cultured MCs (supplementary material,
Figure S1).
A selection of ‘mesenchymal/extracellular matrix sig-
nature’ transcripts is shown in supplementary material,
Table S2. TGF-β1 exposure led to increases in the levels
of Acta2, encoding αSMA, and Vim, encoding vimentin.
These increases, however, were not as great as those
for the following transcripts: Ncam1 and Vcam1, encod-
ing neural and vascular cell adhesion molecules, respec-
tively; and Tnc and Tnn, encoding, respectively, tenascin
C and tenascin N, both of which are extracellular matrix
glycoproteins. Transcripts previously implicated in clas-
sic EMT are listed in supplementary material, Table S3.
Among them, the following transcripts were upregu-
lated: Tgfb1, Tgfb2, and Tgfb3; and Snai1 and Snai2,
encoding snail zinc finger proteins 1 and 2. We found
that the levels of Twist1 and Twist2, encoding transcrip-
tion factors considered to be key effectors of classic
EMT [1,28], were not significantly altered by TGF-β1
(supplementary material, Table S3).
MMT is associated with altered transcripts of BMP
and IGF pathway molecules
RNA-seq (Figure 3A; supplementary material,
Table S4) revealed that control MCs expressed high
levels of Bmp4 but low levels of Bmp7. Bmp4 was
markedly downregulated upon exposure to TGF-β1,
whereas the levels of Grem2, which encodes the BMP
antagonist gremlin 2 [29], increased markedly, as did
those of Bmp1, encoding an atypical BMP family
member that is a secreted metalloprotease implicated
in cartilage formation [30]. TGF-β1 exposure led to
increases in the levels of Igf1 and Igf2, encoding, respec-
tively, IGF1 and IGF2. The levels of Igfbp2, Igfbp4,
Igfbp5 and Igfbp6 decreased. These encode IGFBPs
that alter the interaction of IGFs with their cell surface
receptors, usually decreasing IGF signalling [31]. We
also detected markedly increased levels of Pappa,
which encodes pregnancy-associated plasma protein
A, a secreted metalloproteinase that cleaves IGFBPs,
rendering them inactive [32]. As assessed by qPCR,
the levels of Bmp4 and Igfb4 transcripts also decreased
(Figure 3B). As assessed by ELISA, TGF-β1 exposure
was also associated with decreased concentrations of
BMP4 and IGFBP4 in medium conditioned by MCs
(Figure 3C).
Exogenous BMP4 or IGFBP4 ameliorates
TGF-β1-induced MMT in vitro
We hypothesized that the diminished levels of
BMP4 and IGFBP4 described above might modu-
late TGF-β1-induced MMT. We administered 50 ng/ml
BMP4 or IGFBP4 recombinant proteins to MC cultures.
As assessed by gross morphology and immunostaining
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018; 245: 491–501
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Figure 2. Transcriptome analyses of HBME1-sorted rat MCs. (A) Unsupervised hierarchical clustering by transcript expression. Rows are
expression levels denoted as the z-score, displayed in a high–low (red–blue) colour scale; the numeric scale indicates z-transformation.
Note that levels of numerous transcripts are increased or decreased after 48 h of exposure to 1 ng/ml TGF-β1. Cntl indicates the five
vehicle-only exposed samples. TGF indicates the five parallel cultures exposed to TGF-β1. (B) Selected RNA-seq data displayed as a volcano
plot, with the image annotated for ‘epithelial signature’ transcripts. (C) qPCR for Cdh1, Col4a3, Col4a4, Cng, Pdxl, Snai1, Tjp1, Upk3b, and
Vim (n= 3; mean±SEM).
for ZO1, cingulin, and αSMA, addition of either
protein alone did not affect the phenotype of these
cells (data not shown). In contrast, addition of either
BMP4 or IGFBP4 to TGF-β1-exposed cells (Figure 4A)
preserved aspects of the epithelial phenotype and ame-
liorated the mesenchymal phenotype, as assessed by:
preservation of a cobblestone appearance; less promi-
nent ZO1 cytoplasmic localization; and a reduction in
αSMA immunostaining (Figure 4A), confirmed to be
significant upon quantification (Figure 4B). In contrast,
neither exogenous BMP4 nor IGFBP4 prevented the
loss of cell–cell cingulin localization following addi-
tion of TGF-β1 (Figure 4A). A key event during MMT
is cell migration, so we studied this with a scratch
assay in MC cultures (Figure 4C). MCs exposed to
1 ng/ml TGF-β1 showed enhanced wound closure at
16 h, consistent with increased migration. Addition of
IGFBP4 or BMP4 abrogated this effect (Figure 4D).
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018; 245: 491–501
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Figure 3. MMT is associated with dysregulation of the BMP4 and
IGF pathways. (A) Volcano plot annotated with transcripts encoding
molecules implicated in BMP and IGF signalling. (B) Confirmation
of decreased levels of Bmp4 and Igfbp4 as assessed by qPCR (n= 3;
mean±SEM). (C) As determined by ELISA, the levels of BMP4 and
IGFBP4 were decreased in medium conditioned by cells exposed to
1 ng/ml TGF-β1 (n= 5; mean±SEM).
Exploration of BMP4 in two mouse models
of peritoneal fibrosis
In a mouse model of peritoneal fibrosis induced by
intraperitoneal TGF-β1-expressing adenovirus, there
was attenuation of BMP4 immunostaining of the surface
of the peritoneum (Figure 5A). Next, we ‘genetically
labelled’ peritoneal MCs by activation of the LacZ allele
induced by activating Wt1 promoter-driven Cre recom-
binase. Here, labelled cells and their progeny express
a reporter that can be detected with the XGal reac-
tion. As noted by Lua et al, Wt1 promoter-driven Cre
recombinase activation occurs in a subset of MCs, so
only the fates of the labelled population can be tracked
[18]. Mice were subjected to surgery to induce adhesion
formation, and a subset were treated with BMP4. In
whole mount preparations, we found elongated blue
cells in zones immediately adjacent to the nascent scar,
whereas, in injured mice exposed to exogenous BMP4,
clusters of cuboidal cells were noted (Figure 5B, upper
frames). On histology, cells expressing the reporter
were noted under the peritoneal surface after injury,
whereas, after administration of BMP4, labelled cells
were present on the peritoneal surface (Figure 5B, lower
frames). These observations suggest that BMP4 helps
to restore ‘healthy’ mesothelial morphology following
injury in vivo.
Altered patterns of BMP4 and IGFBP4 expression
in human peritoneal dialysis tissue
Mesothelium was identified in control and peritoneal
dialysis-exposed human peritoneal tissue sections, as
determined by HBME1 immunostaining (Figure 6).
Control peritoneal tissue, from otherwise healthy
patients undergoing incidental hernia surgical repair,
showed positive immunostaining for both IGFBP4
and BMP4 on the peritoneal surface. This pattern
was attenuated in tissue harvested from peritoneal
dialysis patients (Figure 6). Scattered cells below the
mesothelial layer showed positive staining for IGFBP4,
which may represent retention of some mesothelial
characteristics in cells undergoing MMT [10].
Discussion
Previous studies investigating peritoneal MCs gener-
ally analysed cultures obtained solely by enzymatic
digestion of omentum [23,33,34]. A few studies have
enriched for MCs by using procedures such as pos-
itive selection for HBME1 with FACS [15], removal
of CD45-positive cells [35], or sorting for glycopro-
teinM6a (GpM6a)-expressing cells withmagnetic beads
[18]. We found similar levels of MC enrichment by
FACS and magnetic bead sorting: both use positive sort-
ing with HBME1 antibody against a microvillus pro-
tein characteristic of MCs and produced populations in
which 90% of cells were Wt1-positive. Magnetic bead
sorting is a convenient method that bypasses the need
for cell sorting facilities. Whether sorting by the use
of both HBME1 and another specific MC marker, such
as mesothelin or GpM6a, generates greater enrichment
could be addressed in future studies.
Using RNA-seq, we identified numerous ‘epithelial
marker’ RNAs in purified rat MCs, including tran-
scripts encoding ZO1, mesothelin, uroplakin 3B, and
podoplanin, similarly to previous reports. Purified MCs
also expressed high levels of transcripts for several ker-
atins, Wt1, and Msln, encoding the cell surface protein
mesothelin [26]. MCs appear to share certain molecules,
including Wt1 and podocalyxin-like protein 1, with
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018; 245: 491–501
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Figure 4. Application of BMP4 or IGFBP4 to TGF-β1-exposed rat MCs. (A) Cells were maintained for 48 h in either basal medium alone
(control), medium supplemented with 1 ng/ml TGF-β1, or the latter supplemented with either 50 ng/ml BMP4 (TGF-β1+ BMP4) or
50 ng/ml IGFBP4 (TGF-β1+ IGFBP4). Cells were imaged by phase contrast microscopy (top row) or, as shown in subsequent rows, by
immunofluorescence for ZO1, cingulin, and αSMA, with all nuclei counterstained with 4′,6-diamidino-2-phenylindole (blue). Note that
exposure to either BMP4 or IGFBP4 partially preserved the cobblestone pattern of the monolayer, reduced the cytoplasmic localization
of ZO1, and reduced the level of αSMA. In contrast, neither factor rescued the TGF-β1-induced disruption of cingulin. Scale bars: 50 μm.
(B) Quantification of αSMA by immunofluorescence, showing increased immunostaining in TGF-β1-treated versus control cells (n= 5;
mean±SEM). There was a reduction in αSMA expression in cells treated with TGF-β1+ BMP4 or TGF-β1+ IGFBP4. (C) Phase contrast
images showing MC migration into a wound over a period of 16 h under different conditions. Scale bars: 200 μm. (D) Quantification of MC
migration under different conditions (n= 6; mean±SEM). Note that TGF-β1 exposure was associated with more extensive migration than
in controls (n= 6), and that this effect was abrogated when either BMP4 or IGFBP4 was added with TGF-β1.
podocytes, which are specialized epithelial cells within
kidney glomeruli. As for podocytes, the molecular sig-
nature of MCs has certain similarities to that of generic
mesenchymal cells; for example, both epithelia contain
abundant vimentin [36]. Thus, MCs are ‘epithelial-like’
rather than exactly like ‘classic’ epithelia.
The expression of the cell–cell junction protein
E-cadherin, and its downregulation, reflecting the
destabilization of adherens junctions, has been consid-
ered to be a hallmark of EMT, and has been noted in
some MMT studies [23,35,37]. In our study, however,
RNA-seq of HBME1-sorted rat MCs revealed very
low read numbers for Cdh1, the transcript encoding
E-cadherin; moreover, there was no significant change
after TGF-β1 exposure. Furthermore, E-cadherin was
not detected in rat omentum by the use of immunohisto-
chemistry. The literature already points to heterogeneity
of E-cadherin expression by MCs studied in different
contexts. Cells harvested from human omentum, or
collected from dialysis effluent, expressed E-cadherin
[35], but MCs covering the liver [38] or the body wall
[18] of mice did not express E-cadherin in vivo, and nor
did human ovarian MCs [39].
Given the heterogeneity of MCs, depending on their
source, there are unlikely to be exactly the same changes
in gene expression as they undergo MMT. Ruiz-Carpio
et al [35] analysed human peritoneal cells that had
undergone, or were undergoing, MMT. MMT was
associated with increased levels of THBS1, VCAN, and
ITGA11, whereas BMP4 and THBD were downregu-
lated. Inspection of our RNA-seq data revealed similar
significant changes. On the other hand, Ruiz-Carpio
et al noted markedly increased levels of IL33 and
IL6, whereas we found that the former transcript was
expressed but unchanged after TGF-β1, and the latter
was not expressed. Moreover, Ruiz-Carpio et al also
noted markedly decreased levels of AQP1, MUC16,
and VTN. In our arrays, the former two transcripts
were expressed but unchanged by TGF-β1, whereas
the latter was not expressed. Moreover, because MCs
are not typical epithelial cells, MMT molecular profiles
are unlikely to be exactly the same as for EMT. In
our RNA-seq study, Snai1, Snai2 and Zeb2 were all
significantly upregulated in TGF-β1-induced MMT,
and the levels of all three tended to increase in typical
EMT. Conversely, we did not detect TGF-β1-induced
changes in either Cdh2, encoding the cell–cell junction
protein N-cadherin, or in Twist1 and Twist2, encoding
transcription factors: all three have been implicated in
typical EMT. Collectively, these observations support
the idea that that there are unlikely to be exactly the
same changes in gene expression in all forms of EMT
or MMT.
In the current study, Sox9, encoding sex-determining
region Y-box 9, was significantly upregulated in MMT.
This transcription factor has been implicated in fibro-
sis [40], and probably synergizes with SNAIL1 or
SNAIL2 to drive EMT [41,42]. The role of Sox9 in
regulating MMT and peritoneal fibrosis warrants fur-
ther investigation. Wt1 is a transcription factor that
regulates the balance between EMT and MET dur-
ing development [43,44]. In the current study, purified
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Figure 5. BMP4 in murine models of peritoneal fibrosis. (A)
Immunostaining for cytokeratin in the peritoneum of mice showed
diminished mesothelium-specific expression in response to TGF-β1
adenovirus (AD) as compared with control (AdDL); nuclei were
stained with 4′,6-diamidino-2-phenylindole. In response to TGF-β1
overexpression, the peritoneum was extensively thickened, as
shown by Masson’s trichrome, with near-complete loss of surface
BMP4 immunostaining. Scale bars: 100 μm. (B) After surgical injury,
the peritoneum ofWt1 lineage tracing mice was stained with XGal.
Cells expressing the LacZ reporter gene appear blue, and repre-
sent the fates of subsets of MCs and/or their progeny. The top two
frames show whole mounts, looking down on the peritoneal sur-
face. Injured mice that received vehicle alone (left frame) had elon-
gated and spindle-shaped labelled cells, whereas cobblestone-like
cell clusters were seen in similarly injured mice that had received
BMP4 (right frame). Scale bars: 100 μm. The lower two frames show
the histology of the peritoneum, with eosin (pink) counterstaining:
the peritoneal surface is at the top. Injured mice receiving vehicle
alone (left frame) showed labelled cells (arrows) below the surface
(arrowheads) of the peritoneum. In injured mice that had received
BMP4 (right frame), labelled cells (arrows) were noted on the sur-
face of the peritoneum. Scale bars: 20 μm. Representative images
from n= 3 in each group.
MCs expressed high levels of Wt1, but these showed
no significant change in response to TGF-β1. Another
group, analysing pleural MCs, detected MMT when
Wt1 was experimentally downregulated [45]. Thus,
downregulation ofWt1 can be associatedwithMMT, but
appears not to be essential for TGF-β1-induced MMT in
our current study.
We also found that TGF-β1 exposure led to upregula-
tion of transcripts encoding tenascins C and N. Tenascin
Figure 6. Human fibrotic tissue shows altered patterns of BMP4
and IGFBP4. Human control peritoneum or thickened peritoneum
samples from peritoneal dialysis patients were immunostained
for HBME1 to identify mesothelium. Control peritoneum showed
prominent mesothelial IGFBP4 and BMP4 immunostaining, which
was attenuated in peritoneal dialysis samples. In the peritoneal
dialysis samples, scattered IGFBP4-positive cells were noted below
the peritoneal surface. Scale bar: 100 μm.
C is an extracellular matrix protein that has been found
to inhibit cellular adhesion to fibronectin and has been
recently proposed as a biomarker in peritoneal dialysis
associated with poor membrane function [46]. Tenascin
N is a member of the tenascin family that has been pre-
viously associated with neurite outgrowth, and appears
not to have been previously highlighted in MMT, so it is
worthy of further investigation. Upregulation of neural
cell adhesion molecule 1 has been reported to promote
the formation of focal adhesions inmesothelium-derived
tumours [47], but a possible functional role in MMT is
yet to be elucidated. Vascular cell adhesion molecule
1, which is important for leukocyte adhesion, was also
induced by TGF-β1; it has previously been reported to
be upregulated in MCs exposed to advanced glycation
end-products [48,49], and the soluble form has been
reported to inhibit MMT [50].
We hypothesized that, if the molecular signature of
MMT could be better defined, these insights could
be exploited to block this pathological cellular transi-
tion. We discovered that, in response to TGF-β1, MCs
showed robust downregulation of BMP4. Apart from
BMP1, which is a metalloprotease, BMPs are secreted
growth factors belonging to the TGF-β superfamily,
which bind to dimers of BMP receptors I and II, elic-
iting intracellular signalling via SMAD phosphoryla-
tion. BMP4 is required for gastrulation and for lung,
heart and kidney development [51]. We reasoned that
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018; 245: 491–501
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org www.thejournalofpathology.com
Mesothelial molecular signatures 499
the TGF-β1-induced depletion of BMP4 might itself
modulate MMT. Indeed, recombinant BMP4 partially
prevented TGF-β1-inducedMMT, as indicated by reten-
tion of membranous ZO1 localization, lack of αSMA
induction and reduced cell migration in vitro. More-
over, we found that BMP4 immunostaining on peri-
toneal surfaces was attenuated versus healthy controls
in human peritoneal dialysis tissue and in a mouse
model of TGF-β1-induced peritoneal fibrosis. Finally,
genetic lineage tracing of MCs was used in mice with
peritoneal injury. Here, BMP4 administration amelio-
rated injury-induced shape change andmigration of cells
expressing the reporter gene. We interpret these results
as showing that genetically labelled MCs, and/or their
progeny, move under the surface of the injured mesothe-
lium, as also concluded by Lua et alwhen they examined
a model of chlorhexidine gluconate-induced fibrosis
[18]. Our findings demonstrate a distinctiveMMT signa-
ture, and highlight the therapeutic potential for BMP4 to
reduce MMT. Future experiments will be needed, how-
ever, to determinewhether BMP4 ameliorates the degree
of scarring in vivo. Although this is a novel finding
with regard to MMT, application of BMP4 was shown
to reduce retinal epithelial cell EMT in a similar man-
ner [52]. BMP7 has been shown to ameliorate MMT in
previous studies, and BMP7 and BMP4 signal through
similar pathways [53]. Our RNA-seq data showed that
Bmp4 was highly expressed in rat MCs, whereas Bmp7
read counts were low; moreover, only Bmp4 was sig-
nificantly downregulated upon exposure to exogenous
TGF-β1 [Bmp4 average reads of 3434 reducing to 1428
with exposure to TGF-β1 (p= 5.09× 10–24); and aver-
age Bmp7 reads at baseline of 80, and 39 upon expo-
sure to exogenous TGF-β1 (p= 0.108). Therefore, of
these two BMP molecules, it is BMP4 that is the key
endogenous factor in our model. In parallel with the
downregulation of BMP4 in MCs undergoing MMT,
there was an increase in the level of the transcript
encoding gremlin-2, a member of the BMP-antagonist
gremlin family [29,54]. Notably, it has been reported
that adenovirus-mediated upregulation of gremlin1 pro-
motes peritoneal fibrosis in mice [55]. We speculate
that BMP4 signalling via phosphorylation of Smad1/5/8
opposes TGF-β1-mediated phosphorylation of Smad2/3
signalling [53]. Thus, the two signalling pathways may
maintain the balance of homeostasis in the mesothelium.
Our transcriptome analyses also revealed that tran-
scripts encoding the growth factors IGF1 and IGF2 were
upregulated during MMT. In parallel, the levels of tran-
scripts encoding IGFBP4 and IGFBP5 were markedly
downregulated. These changes are predicted to lead to an
increase in IGF signalling activity, as IGFBPs lengthen
the half-life of circulating IGF1, owing to their higher
affinity for IGF ligands than the receptors [31]. We
showed that recombinant IGFBP4, like BMP4, ame-
liorated TGF-β1-induced MMT in vitro. Furthermore,
immunostaining for IGFBP4 of peritoneal tissues har-
vested from peritoneal dialysis patients was less promi-
nent in the mesothelial layer, with some evidence of
expression in cells of the submesothelium that might
represent migratedMCs or their progeny. IGF signalling
interacts at several levels with various components of
the TGF-β signalling pathway [56]. In future, it will be
important to determine whether similar interactions may
be regulating IGF-induced MMT in the peritoneum.
Blocking downstream TGF-β1 signalling pathways
may be another way to attenuate MMT; these include
Smad-dependent [57] and Smad-independent pathways,
such as Akt–mammalian target of rapamycin [57],
c-Jun N-terminal kinase [57], Wnt–β-catenin [58],
integrin-linked kinase–glycogen synthase kinase-3β
[59], extracellular signal-regulated kinase–nuclear
factor-κB [33], and mitogen-activated protein kinase
[60]. Another approach, however, based on the findings
from the current study, would be to focus on introducing
BMP4 and IGFBP4 to prevent MMT and peritoneal
fibrosis. Importantly, evidence suggests MMT occurs
in diverse peritoneal pathologies, including surgical
adhesions [61], endometriosis [62], and peritoneal
metastasis [63]. In a rat model of surgical adhesions,
IGFBP4 administration ameliorated peritoneal scarring
[64], although a link to MMT was not explored. Future
studies are required to elucidate whether therapeuti-
cally manipulating BMP4 or IGFBP4 signalling could
ameliorate the severity of these conditions.
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